Innova Captab Limited

NSE: INNOVACAP · Pharmaceuticals · sector

₹998.20NSE close 2026-10-26

Key numbers

Market cap₹5,712 cr

Price₹998.20

52w high / low₹1,354 / ₹622

P/E36.5xSector median 27.9x

P/B5.3xSector median 2.9x

Book value₹189.0

Dividend yield0.20%Sector median 0.48%

ROE15.3%Sector median 11.7%

ROCE15.7%Sector median 12.3%

OPM14.8%Sector median 14.0%

Debt / equity0.32xSector median 0.16x

EV/EBITDA23.2xSector median 18.6x

Interest cover12.1x

Current ratio1.87x

Sales growth 3y–Sector median +9.6%

Profit growth 3y–Sector median +13.3%

PEG1.79x

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹45 cr vs borrowings ₹344 cr (FY26): borrowings are higher by ₹299 cr.
Operating profit covered interest 12.1x in the last 12 months.
Operating cash flow was below net profit in 2 of the last 3 years (FY26, FY25).
Revenue was higher than a year earlier in 4 of the last 4 quarters.
Other income was 6% of net profit in the last 12 months.
Dividend paid in 1 of the last 3 financial years.
Price ₹998.20 on 2026-10-26: -26.3% from the 52-week high, +60.5% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹1,295.30 · low ₹654.20

Quarterly results

₹ cr	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	318	316	315	352	380	450	448	471
EBITDA	50	47	48	52	52	69	65	73
OPM %	15.6%	14.7%	15.2%	14.8%	13.6%	15.4%	14.5%	15.5%
Other income	2	4	3	4	4	2	2	2
Net profit	35	34	30	31	30	42	40	44
EPS (₹)	6.12	5.97	5.17	5.42	5.18	7.37	7.05	7.71
Revenue YoY					+19.5%	+42.3%	+42.3%	+33.9%
Profit YoY					-15.2%	+23.2%	+36.5%	+42.3%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY24	FY25	FY26	TTM
Revenue	1,081	1,244	1,630	1,749
EBITDA	154	186	243	259
Net profit	94	128	143	156
EPS (₹)	18.66	22.41	25.02	27.31
Revenue growth		+15.0%	+31.1%	+34.5%
Profit growth		+36.0%	+11.6%	+20.4%
Dividend / share (₹)	–	–	2.00

Compounded growth	3 years	5 years	Last 12 months
Sales	–	–	+34.5%
Net profit	–	–	+20.4%
EPS	–	–	–
Share price	–	+16.1% (2y)	+22.2%

Balance sheet

₹ cr	FY24	FY25	FY26
Shareholders' equity	831	959	1,082
Borrowings	245	338	344
Cash & equivalents	87	68	45
Total assets	1,321	1,580	1,838
Fixed assets	340	812	823
Capital work in progress	341	23	16
Investments	0	0	0
Receivables	288	332	437
Inventory	144	208	283
Payables	180	202	300

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY24	FY25	FY26
Cash from operations	146	64	115
Cash from investing	-499	-152	-106
Cash from financing	361	92	-22
Capex	287	172	68
Free cash flow	-141	-109	47

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY24	FY25	FY26
ROE %	11.4%	13.4%	13.2%
ROCE %	14.0%	13.4%	14.4%
Debtor days	97	97	98
Inventory days	72	93	98
Payable days	90	90	104
Cash conversion cycle (days)	79	100	92
Working capital days	106	101	96

Shareholding

Holder	% (2026-09-30)
Promoters	50.90%
FIIs	0.84%
DIIs	19.16%
of which Mutual funds	8.66%
of which Insurance	1.29%
Public (non-institutions)	29.09%

Quarter	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters %	50.90%	50.90%	50.90%	50.90%	50.90%	50.90%	50.90%	50.90%

Promoter group	%
Manoj Lohariwala	29.07%
Vinay Kumar Lohariwala	21.81%
Vandana Lohariwala	0.01%
Chhavi Lohariwala	0.01%
Deendayal Choudhary	0.00%
Sita Devi Lohariwala	0.00%
Shyam Sunder Agarwal	0.00%
Vandana Gohlyan	0.00%
Dhruv Lohariwala	0.00%
Anushka Lohariwala	0.00%
Anshika Lohariwala	0.00%
Vishwanath Choudhary	0.00%
Sumitra Devi Choudhary	0.00%
Anju Jajodia	0.00%
Vitthal Aggarwal	0.00%

Public holders above 1%	%
Gian Parkash Aggarwal	10.19%
Archit Aggarwal	8.74%
Clarus Capital I	3.58%
Kotak Mahindra Trustee Co Ltd A/C Kotak Multicap Fund	3.47%
Canara Robeco Mutual Fund	3.47%
360 ONE Special Opportunities Fund - Series 9	2.05%
360 ONE Special Opportunities Fund - Series 10	1.82%
Veena Devi	1.75%
SBI Life Insurance Co. Ltd	1.29%
Invesco India Small CAP Fund	1.24%

36,551 shareholders. Pledged: – of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
INNOVACAP	₹5,712 cr	36.5x	5.3x	15.3%	15.7%	14.8%	–	0.20%

All 185 companies in Pharmaceuticals →

Dividends & corporate actions

Ex-date	Action	Detail
2026-01-30	Dividend	Interim Dividend - Rs 2 Per Share

Documents

Links go to the original files on the exchange website.

About the company

Manufacturing of Pharmaceuticals: Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	INNOVACAP
BSE code	544067
ISIN	INE0DUT01020
Face value	₹10.0
Incorporated	2005-01-03
Website	https://www.innovacaptab.com
Plants (India / abroad)	3 / 0

From the company's filings (BRSR FY26).

Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.